ArticleWorld journal of surgical oncology2025
Preoperative serum magnesium level as a prognostic and predictive biomarker in locally advanced gastric cancer patients receiving neoadjuvant immunochemotherapy.
Article in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Impact of Concomitant Proton Pump Inhibitor Use on Oncologic Outcomes of Neoadjuvant Chemoimmunotherapy in Locally Advanced Gastric Cancer: A Multicenter Real-World Study.Annals of surgical oncology · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundThe global multicenter phase III MATTERHORN trial further validated the scientific rationale and clinical value of our earlier research, demonstrating that the combination therapy significantly improved patient survival outcomes and provided critical evidence for optimizing gastric cancer treatment strategies worldwide. Nevertheless, despite the overall effectiveness of neoadjuvant immunochemotherapy (NICT), approximately half of the patients did not achieve optimal therapeutic responses. Moreover, only a few clinically useful biomarkers can predict the treatment outcomes. The relationship between pre-treatment serum electrolyte levels and treatment outcomes in patients with locally advanced gastric cancer (LAGC) after NICT remains unclear.
methodsA retrospective analysis was conducted on clinical data from 112 patients with LAGC who underwent radical surgery after NICT between 2020 and 2024. Serum electrolyte levels were measured prior to NICT. The associations between serum electrolyte levels and overall survival (OS) and disease-free survival (DFS) were evaluated.
resultsIn the Kaplan-Meier survival analysis of pre-treatment serum electrolytes, only sodium showed a significant association; however, it was not an independent prognostic factor, according to the Cox regression analysis. Low pre-treatment serum magnesium levels were significantly associated with poorer OS (HR = 21.48, P < 0.001) and DFS (HR = 8.730, P < 0.001). Multivariate Cox regression analysis confirmed that low serum magnesium was an independent prognostic factor for both OS (HR = 0.232, P = 0.007) and DFS (HR = 0.274, P = 0.004). Low magnesium levels were more prevalent in patients with signet ring cell carcinoma or positive perineural invasion. Furthermore, low serum magnesium levels were associated with a poor rate of major pathological response (P < 0.0001).
conclusionPre-treatment serum magnesium levels are independent prognostic factors and potential biomarkers in patients with LAGC undergoing NICT. However, prospective studies are required to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.